• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

  • Home
  • About Us
    • Mission and History
    • Grace-Marie Turner bio
    • Who was Galen?
  • Activities
    • Core Activities
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Taking A Courageous Stand On Drugs For Seniors

POSTED BY Galen Institute on November 3, 2000.

The Bridge Forum
A Periodic look at issues in the US presidential race


ALEXANDRIA, Va.–George W. Bush has taken a courageous, although politically risky, approach to providing a prescription drug benefit for Medicare.


He acknowledges Medicare is in dire need of modernization, but instead of tacking an expensive, bureaucratic new program onto this creaky one, Gov. Bush’s proposal would integrate a drug benefit into overall Medicare reform. Bush also acknowledges that some seniors need help right now with their drug costs. He would provide federal subsidies next year to help lower-income seniors through a system of state programs that can more efficiently target and administer the benefits.

Finally, his Medicare reform plan would assure all seniors they would be protected against medical costs, including prescription drugs, that exceed $6,000 a year.

This is a uniquely American cure that can be implemented without crippling drug research or robbing seniors of choice and the benefits of a competitive marketplace.

This is opposed to the approach taken by Vice President Al Gore, which would add an expensive drug benefit to the existing Medicare program. Far from advancing reform, this move would halt reform in its tracks. And seniors would suffer.

Although Gore says otherwise, Medicare inevitably would control the availability of drugs just as it now controls when, where and how seniors can obtain other health-care services.

Medicare managers soon would develop complex lists of permitted drugs and eventually impose limits on how much it would pay for them. This would wind up hurting the very research that provides the drugs seniors are so desperate to get.

Bush recognizes the pharmaceutical industry must be free to conduct research without constraints of price controls and restrictive government formularies.

The army of men and women devoting their lives to medical research must be free to continue the war on cancer, diabetes, heart disease and other life-threatening illnesses without political intervention.

This sharp difference of vision matters. Forbes magazine recently reported on new research in cancer biology that would trigger the switch inside cancer cells that tells them to die. This revolutionary research could support and even replace radiation, chemotherapy and surgery, and make them seem as barbaric tomorrow as blood leeching does to us today.

But these breakthroughs won’t come if the pharmaceutical industry’s $26 billion in annual research investment is choked off by Gore’s poorly conceived prescription drug benefit.

France provides a chilling example: It strictly regulates both manufactures’ prices and retail margins. It’s no coincidence that of the all the drugs developed globally between 1975 and 1994, France is at the bottom of the list with 3 percent of the total. By contrast, the United States, with its free market system, produced 45 percent of new drugs.

If we want ensure that the potential medical miracles of this century are indeed discovered, the private research industry needs to be supported, not attacked, by government.

Medical miracles come through hard work, risk and protection of intellectual property. Bush’s policy initiatives look to the future with a vision of these extraordinary possibilities.

GRACE-MARIE ARNETT is president of The Galen Institute, an Alexandria, Va.-based research organization that focuses on free-market health reform. Readers may e-mail her at galen@galen.org. Her views are not necessarily those of BridgeNews, whose ventures include the Internet site www.bridge.com.

OPINION ARTICLES and letters to the editor are welcome. Send submissions to Sally Heinemann, editorial director, BridgeNews, 3 World Financial Center, 200 Vesey St., 28th Floor, New York, N.Y. 10281-1009. You may also call (212) 372-7510, fax (212) 372-2707 or send e-mail to opinion@bridge.com.

Filed Under: Uncategorized

Primary Sidebar

Our Annual Report

Health Care Choices 20/20:

A Vision for the Future

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Policy Consensus Group
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • Sun Sentinel
    • The Daily Signal
    • The Heritage Foundation
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute at Donors. © 2023; · Log in